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Abstract
Background: Human immunodeficiency virus (HIV-1) exclusively selects and utilizes tRNALys,3 as
the primer for initiation of reverse transcription. Several elements within the TΨC stem loop of
tRNALys,3 are postulated to be important for selection and use in reverse transcription. The post-
transcriptional modification at nucleotide 58 could play a role during plus-strand synthesis to stop
reverse transcriptase from re-copying the tRNA primer. Nucleotides 53 and 54 within the TΨC
stem loop of the tRNA have been shown to be important to form the complex between tRNA and
the HIV-1 viral genome during initiation of reverse transcription.
Results:  To further delineate the features of the TΨC stem loop of tRNALys,3 in reverse
transcription, we have developed a complementation system in which E. coli tRNALys,3 is provided
in trans to an HIV-1 genome in which the PBS is complementary to this tRNA. Successful selection
and use of E. coli tRNALys,3 results in the production of infectious virus. We have used this single
round infectious system to ascertain the effects that different mutants in the TΨC stem loop of
tRNALys,3 have on complementation. Mutants were designed within the TΨC loop (nucleotide 58)
and within the stem and loop of the TΨC loop (nucleotides 53 and 54). Analysis of the expression
of E. coli tRNALys,3 mutants revealed differences in the capacity for aminoacylation, which is an
indication of intracellular stability of the tRNA. Alteration of nucleotide 58 from A to U (A58U),
T54G and TG5453CC all resulted in tRNALys,3 that was aminoacylated when expressed in cells,
while a T54C mutation resulted in a tRNALys,3 that was not aminoacylated. Both the A58U and
T54G mutated tRNALys,3 complemented HIV-1 replication similar to wild type E. coli tRNALys,3. In
contrast, the TG5453CC tRNALys,3 mutant did not complement replication.
Conclusion: The results demonstrate that post-transcriptional modification of nucleotide 58 in
tRNALys,3 is not essential for HIV-1 reverse transcription. In contrast, nucleotides 53 and 54 of
tRNALys,3 are important for aminoacylation and selection and use of the tRNALys,3 in reverse
transcription.
Background
The major steps in reverse transcription of retroviral
genome have been known for some time [1]. The initia-
tion of reverse transcription occurs at the 5' end of the
viral genome at a site designated as the primer-binding
site (PBS) [1]. The PBS is an 18-nucleotide region that is
complementary to the 3' terminal 18-nucleotides of the
tRNA primer used for initiation [1-3]. The reverse tran-
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scriptase extends the bound tRNA primer from the PBS
resulting in the synthesis of minus strong stop DNA [4].
The reverse transcriptase then translocates to the 3' end of
the viral RNA genome and proceeds to generate a com-
plete minus-strand DNA copy of the viral RNA genome.
The RNaseH activity of the viral encoded reverse tran-
scriptase degrades the RNA copy of the viral RNA genome.
Incomplete processing of the RNA by the RNaseH activity
generates RNA primers for plus-strand DNA synthesis [4].
During plus-strand synthesis, the reverse transcriptase
copies the tRNA primer that is attached to the minus-
strand DNA to generate a plus-strand copy of the PBS.
Complementation between the plus- and minus-strand
PBS facilitates the completion of the viral genome, desig-
nated as the provirus.
The vast majority of the studies that have analyzed the
mechanistic events of reverse transcription have utilized in
vitro  systems comprised of tRNA, reverse transcriptase,
nuclear capsid and synthetic viral RNA/DNA templates.
Previous studies have found that the tRNALys,3 and the
HIV-1 genome form a complex RNA structure for initia-
tion of reverse transcription. As a consequence of this
tRNA:RNA genome interaction, the tRNALys,3 structure is
disrupted and new intramolecular bonds are formed. One
important new RNA:RNA interaction is between nucle-
otides 53 and 54 and the first two nucleotides of tRNALys,3
[5,6].
While in vitro studies have been informative in under-
standing the aspects of reverse transcription, they do not
completely recapitulate all of the events in replication of
the viral RNA genome. Our laboratory has approached
this problem by generating HIV-1 proviruses that require
the addition of exogenous tRNA for infectivity. In previ-
ous studies, we utilized an HIV-1 proviral genome in
which the PBS had been mutated to be complementary to
yeast tRNAPhe [7-10]. We found that the replication of this
genome could be complemented if yeast tRNAPhe was sup-
plied in trans. In vitro systems with synthetic tRNA/viral
templates have been used to characterize many of the fea-
tures of reverse transcription [11]. An important question
that has been addressed using these systems is the role of
modified tRNA bases that might play a role in stopping
the reverse transcriptase during the plus-strand DNA syn-
thesis to prevent complete copying of the tRNA primer.
Since the completion of the proviral genome is facilitated
by complementarity between the minus- and plus-strand
DNA copies of the PBS, additional sequences in the plus-
strand copy of the PBS as a result of copying of the tRNA
primer would compromise the completion of the proviral
genome. Previous studies have suggested that the methyl-
ated adenosine residue at position 58 (A58) of the tRNA
could be a stop signal for the reverse transcriptase [12-14].
Support for this result comes from studies by Renda et al.
who found that tRNALys,3 engineered to not be methylated
at A58 residue conferred a level of resistance to cells
expressing this tRNA [13,14]. Additional studies though
have suggested that the methylated A58 residue is not the
sole stop determinant in plus-strand DNA synthesis [12].
In a recent study, we have engineered a complementation
system which utilizes an HIV-1 proviral genome in which
the PBS has been altered to be complementary to the 3'
terminal 18-nucleotides of E. coli tRNALys,3  [15]. This
tRNA maintains many of the unique transcriptional mod-
ifications found in mammalian tRNALys,3, and when
expressed in mammalian cells, has been shown to be ami-
noacylated indicating that it is fully functional [15]. Thus,
this system provides an excellent opportunity to directly
address the role of the modified nucleotides and tRNA
structure in HIV-1 reverse transcription. In the current
study, we have found that E. coli tRNALys,3 with mutations
at nucleotides 58, 54 and 53 in the TΨC loop region have
varied effects in the production of infectious HIV-1. The
results of our studies demonstrate that features in the TΨC
loop of tRNALys3 are important for the selection and use of
the tRNA as a primer for HIV-1 reverse transcription.
Materials and methods
Tissue culture
293T cells, JC53-BL cells, and HeLa H1 cells were main-
tained in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 1%
antibiotic (Gibco/BRL, Gaithersburg, MD). All cells were
cultured in 37°C incubator supplied with 5% CO2.
Plasmid construction
The LS9 plasmid containing E. coli tRNALys,3 gene and LS9
plasmid containing mammalian tRNALys,3 gene were con-
structed as previously described [15]. The E. coli tRNALys,3
gene in LS9 is located downstream of the human
U6snRNA promoter. The A58 in E. coli tRNALys,3 was
mutated to T using the QuickChange Side-Directed Muta-
genesis (Stratagene, La Jolla, CA) with Ec A58U primers:
(Ec A58U forward)
5'GGTCGTGCAGGACATGAACCTGCGAC3', (Ec A58U
reverse) 5'GTCGCAGGTTCATGTCCTGCACGACC3'. T54
in E. coli tRNALys,3 was substituted to G with Ec T54G
primers: (Ec T54G forward)
5'CAATTGGTCGCAGGATCAAGTCCTGCACGACCC3',
(Ec T54G reverse)
5'GGGTCGTGCAGGACTTGATCCTGCGACCAATTG3'.
T54 in E. coli tRNALys,3 was also substituted to C with Ec
T54C primers: (Ec T54C forward)
5'CAATTGGTCGCAGGCTCAAGTCCTGCACGACCC3',
(Ec T54C reverse)
5'GGGTCGTGCAGGACTTGAGCCTGCGACCAATTG3'.
TG5453 together were substituted to CC with EcTG/CC
primers: (Ec TG/CC forward)Virology Journal 2007, 4:5 http://www.virologyj.com/content/4/1/5
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5'GACTTTTAATCAATTGGTCGCAGCCTCAAGTCCTGCA
CGACCC3', (Ec TG/CC reverse)
5'GGGTCGTGCAGGACTTGAGGCTGCGACCAATTGATT
AAAAGTC3'. All mutations were verified by DNA
sequencing.
The PBS of the proviral HIV-1 genome (NL4-3) was sub-
stituted for a PBS complementary to the 3' terminal 18-
nucleotides of E. coli tRNALys,3  by mutagenesis as
described in [15]. A PBS shuttle vector with the substi-
tuted PBS was digested using the restriction enzymes
BssHII and HpaI in order to release the fragment contain-
ing the E. coli tRNALys,3 PBS region (an 868-bp fragment).
The isolated fragment was ligated into the pNL4-3, which
was also digested using the enzymes BssHII and HpaI.
Resulting HIV-1 proviral mutant was labeled NL4-
EcoLys3. Final mutants were verified by DNA sequencing.
DNA transfections
Co-transfections were performed according to the proto-
col for the Fugene 6 Transfection Reagent (Roche Molecu-
lar Biochemicals, Indianapolis, IN). Briefly, 293T cells
were seeded at a concentration of 2 × 105 cells per well in
6-well plates. 500 ng of NL4-EcoLys3 and 100 ng, 250 ng,
500 ng or 1000 ng LS9 plasmids encoding E. coli tRNALys,3
(wild type or mutations) and 3 μl Fugene reagents were
added to 100 ul of DMEM. These mixtures were incubated
at room temperature for approximately 45 minutes then
added drop-wise to 6-well plates. The cells were supplied
with fresh media 24 hours post transfection. Supernatants
were collected approximately 48 hours post transfection,
centrifuged at 3,000 g, and used in JC53-BL assay to deter-
mine luciferase activity, which has been determined to
correlate to units of infectious virus that is being tested.
Supernatants were also assayed for HIV-1 p24 antigen
(Beckman Coulter, Miami, FL).
Analysis of virus infectivity
Serially diluted supernatants collected from co-transfec-
tions were used to infect JC53-BL cells to determine viral
infectivity. JC53-BL cells were seeded 24 hours pre-infec-
tion. Infected cells were incubated for 2 hours in 37°C
incubator supplemented with 5% CO2. After 2 hours,
DMEM with 10% FBS was added to each well and the cells
ere incubated for additional 48 hours. To determined luci-
ferase activity, cells were lysed using M-PER Mammalian
Protein Extraction Reagent (Pierce, Rockford, IL) and
approximated 20 μL of each lysed sample were transferred
to a microplate. Reporter Lysis Buffer (Promega, Madison,
WI) was added to each sample in the microplate and the
light intensity was measured using a Tropix TR717 Micro-
plate Luminometer (Applied Biosystems, Foster City, CA).
Uninfected cells in wells represented background luci-
ferase activity which was subtracted from all other sam-
ples. Relative Light Units (RLu) per mL were calculated by
dividing the luciferase values by their corresponding dilu-
tions. The total amount of virus was determined by the
p24 ELISA. The amount of infectious virus was deter-
mined as RLu per nanogram p24.
Analysis of E. coli tRNALys,3 expressed in mammalian cells
E. coli tRNALys3 plasmids were transfected into 293T cells,
and total RNA was extracted 48 hours post transfection
under acidic conditions to maintain the amino acid-tRNA
bond [15]. One-half of the RNA sample was treated with
high pH (pH 9) to serve as a de-aminoacylated control.
The samples were separated in an acidic polyacrylimide
gel as previously described [15]. Northern blot was carried
out with NorthernMax-Gly kit (Ambion) using previously
described conditions for isolation of total RNA [15]. The
probe for E. coli tRNALys,3
5'GGTCGTGCAGGATTCGAACCTGCGACCAATTGATTA
AAAGTCAACTGCTCTACCAACTGAGCTAACGAC3' was
phosphorylated using the ready to-go kit (Amersham)
with [γ-32P-ATP]. Hybridization was carried out under
standard conditions. The blots were exposed to X-ray film
which was developed using an SRX-101A developer
(Konica, Wayne, NJ).
PCR and DNA sequence analysis of the PBS regions from 
integrated proviruses
High molecular weight DNA (HMW) was collected using
Wizard Genomic DNA Purification Kit (Promega, Madi-
son, WI). The region encompassing the PBS was amplified
by PCR using the following primers: (forward)
5'TAGACCAGATCTGAGCCTGGGAGCTC3' and (reverse)
5'CTCCTTCTAGCCTC CGCTAGTC3'. Following PCR, the
products were run on 1% agarose gel and gel extracted
with QIAquick Gel Extraction Kit (Qiagen, Valencia, CA)
and used for DNA sequencing.
Results
Construction of E. coli tRNALys,3 mutants and HIV-1 
proviral genomes
In a recent study, we have described a complementation
system which relies on the addition of E. coli tRNALys,3 in
trans to complement an HIV-1 proviral genome in which
the PBS was altered to be complementary to the 3' termi-
nal 18-nucleotides of this tRNA [15]. E. coli tRNALys,3
shares many features with mammalian tRNALys,3. In a pre-
vious study, we demonstrated that transfection of the pro-
viral genome with a PBS to E. coli tRNALys,3  into
mammalian cells required complementation by E. coli
tRNALys,3cDNA in order to produce infectious virus [15].
Titration of increasing amounts of E. coli tRNALys,3 plas-
mid resulted in corresponding increase in levels of infec-
tious virus.
In the current study, we have constructed mutants in the
E. coli tRNALys gene in which the A58 was mutated to TVirology Journal 2007, 4:5 http://www.virologyj.com/content/4/1/5
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(A58U) (Figure 1A). To characterize the effect of this
mutation we ascertained whether the tRNA could undergo
aminoacylation following transfection of tRNA plasmid
into mammalian cells. The capacity of the tRNA to
undergo aminoacylation is indicative of proper identity
elements, three-dimensional folding of the tRNA, and,
most probably, inclusion into the translational machinery
(Figure 1B). Following transfection of the wild type E. coli
tRNALys,3  and  E. coli tRNALys,3  A58U into mammalian
cells, we analyzed these cells for the presence of aminoa-
cylated E. coli tRNALys,3. The wild type and mutants were
expressed in mammalian cells following transfection and
aminoacylation (Figure 1B). Thus, the lack of post-tran-
scriptional A58 modification did not influence the capac-
ity of this tRNA to undergo expression, transport from the
nucleus to the cytoplasm, aminoacylation, and presuma-
bly inclusion into the translational machinery.
Next, we wanted to determine whether the mutant E. coli
tRNALys,3 A58U could complement the HIV-1 proviral
genome in which the PBS was altered to be complemen-
tary to the 3' terminal 18-nucleotides of this tRNA (Figure
1C). For these studies, we utilized increasing amounts of
plasmids encoding the wild type and mutant E. coli tRNA-
Lys,3 in the transfection. The amount of virus released from
the transfections was determined using the JC53-BL assay.
Complementation of the proviral genome was demon-
strated following transfection of the wild type E. coli tRN-
ALys,3. The levels of infectious virus increased reaching a
plateau at approximately 500 ng of plasmid encoding the
tRNAs. Importantly, we also found a similar level of com-
plementation following transfection of E. coli tRNALys,3
A58U, confirmed by production of infectious virus. In this
case, we found no clear difference between the wild type
and mutant tRNA for the capacity to complement the
HIV-1 proviral genome. Analysis of the PBS from the inte-
grated proviruses after infection revealed that all were
complementary to E. coli tRNALys,3 (data not shown). We
found no evidence for additional tRNA sequences (after
nucleotide A58) as would be expected if the reverse tran-
scriptase had not stopped during copy of the tRNA during
plus-strand synthesis. Collectively, the results of these
studies show that the A58U mutation in tRNALys,3 does
not impact on the capacity of this tRNA to be selected and
used in HIV-1 replication.
Characterization of mutations within the TΨC stem loop 
of E. coli tRNALys,3
Nucleotides within the TΨC stem loop were modeled to
interact with HIV genome in forming the initiation com-
plex between tRNA and viral RNA (Figure 3) [5,6]. A sec-
ond interaction has also been found involving the tRNA
and nucleotides within the stem of the TΨC stem loop
that has also been termed the primer activation signal
(PAS) [16]. To begin to address the importance of the
TΨC stem loop, we made additional mutations in E. coli
tRNALys,3. The first mutation targeted nucleotide 54 which
is a T (Figure 2A). Two mutations were made in which the
thymidine at nucleotide 54 was changed to a G or C
(T54G or T54C, respectively). We also made a third muta-
tion in which the TG at nucleotides 54 and 53 were altered
to Cs (TG5453CC) (Figure 2B). Each of these mutations
were postulated to affect elements of the initiation com-
plex between the tRNA and HIV viral genome.
We first characterized the effects of these mutation on E.
coli tRNALys,3. We determined whether the mutant tRNAs
would be expressed and aminoacylated. The capacity of
the tRNA to be aminoacylated correlates with the stability
of this tRNA within the cell. Analysis of the aminoacyla-
tion status reveals that both T54G and TG5453CC E. coli
tRNALys,3  mutants were predominately aminoacylated
within the cell, indicating their intracellular stability. In
contrast, the T54C mutation in E. coli tRNALys,3 was poorly
aminoacylated and consequently expressed at a lower
level than the other mutants (data not shown).
We next analyzed the capacity of these E. coli tRNALys,3
mutants to complement the replication of the HIV viral
genome with the PBS complementary to E. coli tRNALys,3
(Figure 2C). Fixed amount of pro viral plasmid and
increasing amounts of plasmids encoding wild type or
mutant E. coli tRNALys,3 were co-transfected into mamma-
lian cells. The activity of the resultant virus was deter-
mined using the JC53-BL assay. The mutant T54G E. coli
tRNALys,3  readily complemented the infectivity of the
mutant provirus at levels similar to that of the wild type
tRNA. It was possible that the T54G E. coli tRNALys,3 was
slightly more efficient in complementation as evidenced
by increased levels at lower amounts of plasmid co-trans-
fected with the proviral genome. However, the peak levels
of complementation were similar between T54G E. coli
tRNALys,3 and the wild type E. coli tRNALys,3. Not surpris-
ingly, the mutant T54C E. coli tRNALys,3 did not comple-
ment the infectivity (data not shown). Most probably this
was due to poor levels of expression as a result of inability
to become aminoacylated. Surprisingly, the TG5453CC E.
coli  tRNALys,3 did not complement the mutant proviral
genome, even though this tRNA was expressed and ami-
noacylated in cells. This lack of complementation was
observed throughout the entire range of the plasmids used
in the titration. Thus, the results of these studies demon-
strate that mutations within the TΨC loop can impact the
stability of the tRNA (T54C) as well as the capacity of this
tRNA to be selected and used in HIV-1 reverse transcrip-
tion. The results support a role for nucleotides 54 and 53
within the TΨC stem loop in the use of tRNALys,3 in reverse
transcription.Virology Journal 2007, 4:5 http://www.virologyj.com/content/4/1/5
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Complementation of HIV-1 infectivity with E. coli tRNALys,3 A58U mutant Figure 1
Complementation of HIV-1 infectivity with E. coli tRNALys,3 A58U mutant. Panel A. Diagram of E. coli tRNALys,3 
A58U mutant. The base change A58U is indicated. Boldface nucleotides indicate the 3' 18-nuleotides complementary to the 
PBS of HIV-1 (E. coli tRNALys,3). 
Panel B. Expression and aminoacylation of E. coli tRNALys,3 and E. coli tRNALys,3 A58U in 293T cells following transfection. 
Total RNA was isolated under acidic conditions to stabilize the amino acid tRNA bond. Approximately one-half was treated 
with high pH as to break the amino acid-tRNA bond (deAA). Samples were run on an acid polyacrylamide gel and blotted into 
nitrocellulose. All samples were analyzed with a probe specific for tRNALys,3 [15]. The migration of aminoacylated tRNA (Lane 
2) and deacylated controls (Lane 1) are denoted as AA and deAA, respectively. NT is RNA from non-transfected 293T cells. 
Panel C. Infectivity of NL4-EcoLys3 complemented by E. coli tRNALys,3 or E. coli tRNALys,3 A58U. 0.5 μg NL4-EcoLys3 was co-
transfected with 0.1, 0.25, 0.5, 1.0 μg plasmids encoding E coli tRNALys,3 or mutant into 293T cells. Virus was collected 48 hours 
post transfection. The amounts of infectious virus produced from transfection were determined using the JC53-BL bioassay 
which measures luciferase activity [19]. The infectivity is determined by the amount of luciferase is divided by the amount of 
virus as determined by p24 ELISA, to give RLu per nanogram. Values are the average (+SD) from three assays.
20
40
60
80
100
0.2 0.4 0.6 0.8 1.0
WT
A58U
R
L
u
/
n
g
μgrams plasmid  
A
C
OH
C
3'
C
C
A
G
C
CC
A
A
U
C
C
G
60
A G G
Ψ
U
50
C
U
C
A
A
D
G
G
G
G
G
Anticodon-loop
G
U
C
G m7
G
A
G
A
U
U
U
S
10
20
70
5'
A
30
A
C
A
U
CUC
Α
G
G
U
Gm2
C
Ψ
A
U
G D
D
C
U
U
A t6
A
40
U
G
A
Acceptor-stem
TΨC-loop
D-loop
A58U
G
T
G
A
NT WT A58U
AA
deAA
1 1 2 2
B
C
CVirology Journal 2007, 4:5 http://www.virologyj.com/content/4/1/5
Page 6 of 10
(page number not for citation purposes)
Complementation of NL4-EcoLys3 with E. coli tRNALys,3 mutants Figure 2
Complementation of NL4-EcoLys3 with E. coli tRNALys,3 mutants. Panel A. Diagram of E. coli tRNALys,3 T54G and 
T54C. The mutated nucleotide is indicated by a circle. 
Panel B. Nucleotide diagram E. coli tRNALys,3 TG54GG. The mutated nucleotides are indicated by circles. 
Panel C. Infectivity of NL4-EcoLys3 complemented by E. coli tRNALys,3, E. coli tRNALys,3 T54G, and E. coli tRNALys,3 TG5453CC 
mutants. 293T cells were co-transfected with 0.5 μg of proviral plasmid and with tRNA plasmids that were titrated in at the 
indicated quantities. Infectivity, for complementation of plasmid NL4-EcoLys3 with E. coli tRNALys,3 T54G is specified by open 
circle; NL4-EcoLys3 with wild type E. coli tRNALys,3 is specified by closed circle; NL4-EcoLys3 with E. coli tRNALys,3 TG5453CC 
is specified by open square. The infectivity is determined by the amount of luciferase determined by JC53-BL assay divided by 
amount of virus (p24 ELISA) to obtain RLu per nanogram. Values are the average (+SD) from three assays.
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Potential RNA secondary structure of the complex formed by NL4-EcoLys3 viral RNA and E. coli tRNALys,3 Figure 3
Potential RNA secondary structure of the complex formed by NL4-EcoLys3 viral RNA and E. coli tRNALys,3. 
The tRNA:RNA structure was adapted from that described in previous studies [5,6]. The mutations at nucleotides 54 and 53 
of E. coli tRNALys1,2 are boxed. The T54G mutation would be predicted to destabilize the interaction (G:G), while the 
TG5453CC mutation should stabilize by favorable G:C interaction.
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Discussion
Previous studies have examined the role that post-tran-
scriptional modification of the tRNALys,3 have on HIV-1
reverse transcription [12-14,17]. In one study, an in vitro
system was established which recapitulates minus-strand
strong stop synthesis and the plus-strand DNA synthesis.
The results from these studies establish that the modified
nucleotide A58 of the natural tRNALys,3 was only partially
effective as a stop signal [12]. The reverse transcriptase in
some instances could transcribe as far as the hypermodi-
fied adenosine at A37 in the anticodon loop [17]. Based
on the results of these studies, the authors concluded that
the modified nucleoside at A58, which is present in all
tRNALys,3 molecules, appears to be important for both the
efficacy and fidelity of plus-strand DNA transfer. Renda et
al., extended this work and constructed cell lines or
derived MuLV based vectors, to express the A58U tRNA-
Lys,3 [13,14]. Analysis of the replication of HIV-1 in these
cells revealed that it was slower than that observed for rep-
lication of the virus in cells which did not express the
mutated tRNALys,3, although the virus did eventually grow
in these cells. Analysis of the resultant virus revealed that
it had not undergone alteration in the PBS region. How-
ever, the inhibition of HIV-1 replication varied in individ-
ual cell clones, with some cell clones showing no
inhibition. In addition, the levels of the mutated tRNALys,3
were not determined in the individual cell lines, making it
difficult to evaluate how the levels of mutant tRNALys,3
effect viral replication and cellular metabolism. The
results of these experiments suggested that mutations in
A58 would have been expected to affect the capacity to
produce infectious HIV-1. To further explore the potential
of the A58 mutation to inhibit HIV-1 replication, we
decided to determine whether the mutant tRNA would
complement HIV-1 replication when provided in trans.
For our studies, we engineered the HIV-1 proviral genome
so that the PBS would be complementary to the 3' termi-
nal nucleotides of E. coli tRNALys,3. In a recent study, we
have shown that E. coli tRNALys,3, when provided in trans
to this HIV-1 proviral genome, results in production of
infectious virus [15]. If the A58 post-transcriptional mod-
ification was important for selection and use as the
primer, we anticipated that co-transfection with the
mutant proviral genome would not result in production
of infectious virus. However, we demonstrated that the
A58U mutant complemented the infectivity of the HIV-1
proviral genome at levels similar to that observed with the
wild type E. coli tRNALys,3. At present, we cannot resolve
the differences from our study with those of Renda et al
[13,14]. The results of our study are consistent with the
possibility that additional features of the tRNALys,3 are
more important than the modified bases for the termina-
tion of plus-strand synthesis [12]. Since our in vivo com-
plementation system has all of the appropriate viral and
host cell proteins available for the process of reverse tran-
scription, which is not the case entirely for the in vitro sys-
tem, it is possible that other protein and RNA elements
can compensate for the lack of modified bases. Indeed,
the in vivo complementation system recapitulates both the
selection process as well as the events in reverse transcrip-
tion. It is also likely that the three dimensional structure
of the tRNA impacts on plus-strand DNA stop [12]. Previ-
ous studies have found a complex refolding of the tRNA
that occurs during initiation of the minus-strand strong
stop DNA synthesis [5,6]. As a consequence, new intramo-
lecular bonds are established in the tRNA. The new tRNA
structure could be a major determinant in the effective
plus-strand strong stop. The viral nucleocapsid could
facilitate the maintenance of the new tRNA structure. The
intracellular in trans complementation system used in the
study then recapitulates the appropriate nucleocapsid-
RNA interactions, which could explain the production of
infectious virus using the tRNALys,3 mutants. Just how the
modified bases affect the new three-dimensional RNA
structure is unknown and will require additional studies.
To further explore the role of nucleotides in the tRNALys,3
TΨC stem loop during reverse transcription, we made
additional mutations at nucleotides 54 and 53. The T54G
mutation in E. coli tRNALys,3 did not affect the capacity of
this tRNA to be aminoacylated or to be used in HIV
reverse transcription. In contrast, mutation T54C resulted
in lack of aminoacylation and consequently this E. coli
tRNALys,3 mutant did not complement HIV replication.
Analysis of the expression level for T54C E. coli tRNALys,3
revealed a decrease, upon comparison to the T54G E. coli
tRNALys,3, and lack of aminoacylation by the lysyl-tRNA
synthetase. The lower levels of expression found for tRNAs
that are unable to undergo aminoacylation is consistent
with previous studies that have shown unaminoacylated
tRNA instability within cells [18]. An interesting result
was obtained with the double mutation TG5453CC. In
this case, the TG5453CC E. coli tRNALys,3 was aminoa-
cylated and generally was produced at levels similar to
that of the wild type tRNA. However, this tRNA did not
complement the HIV-1 proviral genome at all tRNA plas-
mid concentrations tested. At present, we believe that the
TG5453CC mutation in tRNALys,3 precludes or retards the
tRNA from forming an initiation complex with the HIV-1
RNA genome. Previous studies have established that
nucleotides with the TΨC stem loop within the E. coli
tRNALys,3 could be involved in two potential steps during
initiation of HIV-1 reverse transcription. In the first, this
region is postulated to form an intramolecular bond with
the 5' end of tRNA; this RNA:RNA interaction in tRNALys,3
is postulated to help form the structure for the initiation
of HIV reverse transcription [5,6] (Figure 3). However, the
T54G and TG54CC mutations could be predicted to have
different effects on the intramolecular tRNALys,3 interac-
tions formed during initiation. The T54G mutation wouldVirology Journal 2007, 4:5 http://www.virologyj.com/content/4/1/5
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be predicted to destabilize the interaction to an unfavora-
ble base pair between nucleotide 1 and 54 (G:G). In con-
trast, the TG5453CC mutation was expected to promote
this interaction through G:C base pairs. Thus, it was sur-
prising that the T54G mutation in E. coli tRNALys,3 still
allowed complementation, while the TG5453CC mutated
tRNALys,3 did not complement. It is possible that sufficient
base pair interactions still existed to form the initiation
complex, but other tRNA:HIV-l genome interactions were
compromised as a result of the TG5453CC mutation (Fig-
ure 3). A second function for this sequence has been
found to interact with the HIV-1 genome within the U5
region (PAS) [16]. The TG5453CC mutation would have
been predicted to only partially disrupt this interaction,
but it could have been sufficient to inhibit initiation.
Additional studies will be required to further delineate the
critical intra and intermolecular interaction between the
TΨC region of tRNALys,3 and the viral genome for initia-
tion of reverse transcription.
Conclusion
In the current study, we have investigated the contribution
that post-transcriptional modification of tRNALys,3  at
nucleotide A58 and nucleotides within the TΨC stem
loop (54 and 53) have on the capacity of this tRNALys,3 to
be selected and used as the primer for HIV-1 reverse tran-
scription. We found that these mutations, with the excep-
tion of T54C, did not affect the expression of these tRNAs
and the capacity to undergo aminoacylation, and presum-
ably, entrance into the translational processes of the cell.
The capacity of these mutated tRNAs to complement HIV-
1 replication, when provided intracellularly in trans was
determined by co-transfection with a pro viral plasmid in
which the PBS was mutated to be complementary to E. coli
tRNALys,3. From the results of our studies, we conclude
that the post-transcriptional modification at nucleotide
58 is not essential for function of tRNALys,3 in HIV-1 repli-
cation. Nucleotides within the TΨC loop are also impor-
tant for tRNA:HIV-l genome RNA interactions in
initiation of reverse transcription. We found that one
mutant, TG5453CC, could undergo aminoacylation, indi-
cating the tRNA structure was intact, but it did not com-
plement HIV-1 replication even though this mutant
would be predicted to have favorable interactions for the
initiation complex between tRNA and HIV-1 RNA. A sec-
ond mutant, T54G, which would be predicted to not favor
the tRNA:HIV-l genome RNA interaction in the initiation
complex was fully functional for complementation. From
these results, we conclude that a complex interaction
between the HIV-1 viral genome in tRNALys,3 probably
involves multiple, complex RNA:RNA interactions during
primer selection and reverse transcription. The absolute
base pair complementarity are not necessary for these
interactions, consistent with the idea the RNA structures
are dynamic during HIV-1 reverse transcription.
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